IRIS
RUBAGOTTI, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 18.715
AS - Asia 16
SA - Sud America 4
NA - Nord America 1
Totale 18.736
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 18.715
CN - Cina 8
SG - Singapore 5
BR - Brasile 4
VN - Vietnam 3
DO - Repubblica Dominicana 1
Totale 18.736
Salva come PNG Salva come JPEG
Città #
Genova 12.100
Genoa 3.762
Rapallo 1.634
Vado Ligure 1.189
Bordighera 30
Beijing 3
Singapore 3
Ho Chi Minh City 2
Cerquilho 1
Hanoi 1
Mogi Guaçu 1
Padre Paraíso 1
Sangão 1
Santo Domingo Este 1
Totale 18.729
Salva come PNG Salva come JPEG
Nome #
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 222
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 201
Adjuvant immunochemotherapy in colorectal cancer Dukes C. 190
Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials 187
A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group. 174
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 169
"Autologous Bone Marrow Transplantation for Adult Advanced Stage Lymphoblastic Lymphoma in First CR. A Study of the NHLCSG". 162
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. 160
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 160
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 157
A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. 156
Differential expression of nuclear lamins in normal and cancerous prostate tissues 155
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 154
Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa) 154
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 150
Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast 148
Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery 145
Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer? 143
Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer. 142
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. 142
Targeting androgen-independent pathways: new chances for patients with prostate cancer? 142
Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results 141
Switching to aromatase inhibitors in early breast cancer. 141
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer 139
84: [Antibiotic preparation in operations on the large intestine. Experimental study] GF, Rollandi GA. 137
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. 137
Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. 136
Periostin: A Novel Prognostic and Therapeutic Target For Genitourinary Cancer? 136
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. 136
Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death 134
68P * Prognostic value of periostin (PN) expression in early breast cancer (BCa): Long-term mortality outcomes 133
Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial. 132
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial. 131
Prognostic value of nuclear matrix protein expression in localized prostate cancer. 131
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials 131
A randomized trial of 5-fluorouracil alone versus 5-fluorouracil and high dose leucovorin in untreated advanced colorectal cancer patients. 130
Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. 130
48: Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. 130
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. 130
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. 129
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials 129
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients 129
Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer 128
Enterolactone in breast cyst fluid: correlation with EGF and breast cancer risk. 127
Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer. 126
The impact of received dose intensity on the outcome of advanced ovarian cancer. 125
MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. 125
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen. Results of the GROCTA trial. 125
Carboplatin, Doxorubicin, and Cyclophosphamide Versus Cisplatin, Doxorubicin, and Cyclophosphamide: a Randomized Trial in Stage III-IV Epithelial Ovarian Carcinoma" 124
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. 124
VACOP-B Versus VACOP-B Plus Autologous Bone Marrow Transplantation for Advanced Diffuse Non-Hodgkin's Lymphoma: Results of a Prospective Randomized Trial by the Non-Hodgkin's Lymphoma Cooperative Study Group 124
Cytokinetic-based versus conventional chemotherapy in metastatic breast cancer: a randomized study. 124
Cardiovascular disease (CVD) markers in patients(pts) with prostate cancer(PCa) treated with GN-RH agonists(AG) or antagonist(AN): a prospective cohort study 122
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial 121
Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study 121
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study 121
Fattibilità della Terapia Adiuvante Intraperitoneale e Sistemica in Pazienti Operati Radicalmente per Carcinoma del Colon. 120
Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer. 120
Chemoradiotherapy in locally advanced bladder cancer: neoadjuvant and definitive treatment 120
Chemotherapy (CT) versus tamoxifen (T) versus chemoterapy plus tamoxifen (CTT) in patients with node-positive (N+), estrogen receptor-positive (ER+) breast cancer (bca): Very late results of an Italian multicentric trial 120
Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients. 119
A. Lettera a: Journal of Clinical Oncology, 1987; 5, N. 4. 119
Randomized cooperative study of perioperative chemotherapy in breast cancer. 119
Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trial. 119
A large SEER- based study of survival trends in patients with de novo metastatic prostate cancer 118
Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study 117
O-4 Ovarian suppression (OS) and tamoxifen (TAM) as an alternative to chemotherapy in early breast cancer. Long-term results of the GROCTA02 trial 116
Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group 115
Safety of antiandrogen therapy for treating prostate cancer. 115
An Open, Randomised, Multicentre, Phase 3 Trial Comparing the Efficacy of Two Tamoxifen Schedules in Preventing Gynaecomastia Induced by Bicalutamide Monotherapy in Prostate Cancer Patients 115
Complement C3f serum levels may predict breast cancer risk in women with gross cystic disease of the breast. 113
A Randomized Study in Metastatic Breast Cancer (MBC) Comparing Conventional Chemotherapy Vs Chemotherapy with Estrogenic Recruitment." 113
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial 113
The prognostic value of stromal and epithelial periostin expression in human breast cancer: Correlation with clinical pathological features and mortality outcome 113
Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO). 112
Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung. 112
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. 111
Randomized trial of chemoimmunotherapy in advanced non-oat-cell lung cancer. 111
A randomized trial of chemotherapy with or without estrogenic recruitment in locally advanced breast cancer. North-West Oncology Group (GONO) Study, Italy. 111
High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. 111
Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes 111
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer 111
Gynaecomastia: the anastrozole paradox 111
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. 111
Etoposide v etoposide and cisplatin in the treatment of advanced non-small cell lung cancer: a FONICAP randomized study. 110
Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial 110
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. 110
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. 109
Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study. 109
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. 108
Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. 108
D-TRP-6 LH-RH treatment of prostatic cancer. 108
Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients 108
Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. 107
Prednisone plus Gefitinib (pG) versus prednisone plus placebo (ppl) in the treatment of hormone-refractory prostate cancer (HRPC). A randomized phase II trial. 107
Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study 107
Stimulation of human breast cancer in vivo. Experimental findings and clinical results. 106
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, esrogen receptor-positive breast cancer patients: results of a multicentric Italian study. 105
Cerebral metastases secondary to ovarian cancer: still an unusual event. 104
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 104
Totale 12.888
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.599
article - articoli 58.383
book - libri 0
conference - conferenze 240
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.976
Totale 125.198
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021788 0 0 0 100 43 104 49 90 111 125 78 88
2021/20222.048 47 135 131 261 75 153 74 548 112 188 53 271
2022/20231.941 194 105 23 202 364 399 1 142 340 9 134 28
2023/2024898 48 143 16 99 90 154 54 64 35 29 53 113
2024/20252.741 53 235 89 194 422 290 263 427 103 110 228 327
2025/20261.058 484 114 226 234 0 0 0 0 0 0 0 0
Totale 19.001